Abstracts tagged "giant cell arteritis"

Abstract Number: 2688 • 2019 ACR/ARP Annual Meeting
Comparisons of Strategies for Diagnostic Assessment in Giant Cell Arteritis: Results from an International Observational Cohort
K Bates Gribbons¹, Cristina Ponte ², Anthea Craven ³, Joanna Robson ⁴, Ravi Suppiah ⁵, Raashid Luqmani ³, Richard Watts ⁶, Peter Merkel ⁷ and Peter C. Grayson ⁸, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Department of Rheumatology, Hospital de Santa Maria, Lisbon, Portugal, ³University of Oxford, Oxford, United Kingdom, ⁴Faculty of Health and Applied Sciences, University of the West of England, Bristol, United Kingdom, ⁵Department of Rheumatology, Auckland District Health Board, Auckland, New Zealand, ⁶Norwich Medical School, University of East Anglia, Norwich, United Kingdom, ⁷University of Pennsylvania, Philadelphia, PA, ⁸National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health, Bethesda, MD, Bethesda, MD
Background/Purpose: Diagnostic assessment in giant cell arteritis (GCA) is rapidly changing as large-vessel (LV) involvement becomes increasingly recognized and non-invasive vascular imaging techniques become more…
Abstract Number: 1839 • 2019 ACR/ARP Annual Meeting
Different Patterns and Specific Outcomes of Large-Vessel Involvements in Giant Cell Arteritis
Hubert de BOYSSON¹, Eric LIOZON ², Olivier ESPITIA ³, Aurélie DAUMAS ⁴, Mathieu VAUTIER ⁵, Marc LAMBERT ⁶, Jean-Jacques PARIENTI ⁷, Alain MANRIQUE ⁷, David Saadoun ⁸, Kim Heang Ly ², Christian Agard ⁹ and Achille Aouba ¹⁰, ¹University Hospital of Caen, Caen, France, ²Limoges University Hospital, Limoges, France, ³Nantes University Hospital, Nantes, France, ⁴Marseille AP-HM, Marseille, France, ⁵Paris - Pitié salpétrière, Paris, France, ⁶Lille University Hospital, Lille, France, ⁷Caen University Hospital, Caen, France, ⁸AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Department of Internal Medicine and Clinical Immunology, F-75013, Paris, France, Paris, France, ⁹CHU Nantes, Nantes, France, ¹⁰CHU Caen, Caen, France
Background/Purpose: Large-vessel involvements (LVI) in giant-cell arteritis (GCA) include different clinical and imaging patterns that are often pooled together in the published cohorts under the…
Abstract Number: 2665 • 2019 ACR/ARP Annual Meeting
Clinical Outcomes of Patients with Giant Cell Arteritis and Polymyalgia Rheumatica Symptoms Treated with Tocilizumab in Routine Clinical Practice
Sebastian Unizony¹, Robert Spiera ², Jinglan Pei ³, Páris Sidiropoulos ³, Jennie Best ⁴ and John Stone ¹, ¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ²Hospital for Special Surgery, New York, NY, ³Genentech, South San Francisco, CA, ⁴Genentech, Inc., South San Francisco, CA
Background/Purpose: Approximately 50% of patients with giant cell arteritis (GCA) also have polymyalgia rheumatica (PMR) symptoms.1 The purpose of this study was to determine whether…
Abstract Number: 2690 • 2019 ACR/ARP Annual Meeting
Fast Track Clinic (FTC) for Giant Cell Arteritis (GCA) – the United States Experience
Ingeborg Sacksen ¹, Elizabeth Jernberg ¹, Scott Pollock ², Jean Liew ³, Sarah Chung ², R Eugene Zierler ³ and Alison Bays², ¹University of Washington Division of Rheumatology, Seattle, ²University of Washington Division of Rheumatology, Seattle, WA, ³University of Washington, Seattle, WA
Background/Purpose: Giant cell arteritis (GCA) is the most common form of vasculitis in adults and if untreated, may result in visual impairment. Although the gold…
Abstract Number: 1841 • 2019 ACR/ARP Annual Meeting
Resolution of Vascular Inflammation in Patients with Giant Cell Arteritis Receiving Glucocorticoids, Methotrexate or Tocilizumab Treatment: Data from the Italian/German RIGA Study
Verena Schönau ¹, Jessica Roth ¹, Koray Tascilar ², Jürgen Rech ³, Daniela Schmidt ⁴, Torsten Kuwert ⁴, Filippo Crescentini ⁵, Luigi Boiardi ⁶, Massimiliano Casali ⁷, Annibale Versari ⁸, Giulia Pazzola ⁵, Georg Schett ⁹, Carlo Salvarani ¹⁰ and Francesco Muratore¹¹, ¹Rheumatology Unit, University of Erlangen, Erlangen, Germany, ²Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, Erlangen, Bayern, Germany, ³Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany, ⁴Nuclear Medicine Unit, University of Erlangen, Erlangen, Germany, ⁵Rheumatology Unit, Azienda Unita' Sanitaria Locale IRCCS di Reggio Emilia, Reggio Emilia, Italy, ⁶Division of Rheumatology, Azienda Unita' Sanitaria Locale IRCCS di Reggio Emilia, Reggio Emilia, Italy, ⁷Azienda USL-IRCCS di Reggio Emilia, REGGIO EMILIA, Italy, ⁸Nuclear Medicine Unit, Azienda Unità Sanitaria Locale IRCCS di Reggio Emilia, Reggio Emilia, Emilia-Romagna, Italy, ⁹Department of Internal Medicine 3, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany, ¹⁰Division of Rheumatology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, ¹¹Division of Rheumatology, Azienda Unita’ Sanitaria Locale IRCCS di Reggio Emilia, Reggio Emilia, Italy
Background/Purpose: 18F-FDG-PET/CT is a sensitive and comprehensive technique to diagnose giant cell arteritis (GCA). This technique may be also very useful to test whether vascular…
Abstract Number: 2669 • 2019 ACR/ARP Annual Meeting
Survival Trends in Giant Cell Arteritis: A Population-based Cohort Study
Thomas Garvey¹, Cynthia Crowson ¹, Matthew Koster ², Eric Matteson ³ and Kenneth Warrington ², ¹Mayo Clinic Rochester, Rochester, ²Mayo Clinic Rochester, Rochester, MN, ³Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA, Rochester
Background/Purpose: To investigate survival trends in patients with giant cell arteritis (GCA) diagnosed over a 60-year period.Methods: We assembled a population-based incidence cohort of patients…
Abstract Number: 2691 • 2019 ACR/ARP Annual Meeting
Treatment Patterns, Disease Burden and Outcomes in Patients with Giant Cell Arteritis and Polymyalgia Rheumatica
Gary Craig¹, Keith Knapp ², Bob Salim ³, Shalini Mohan ⁴ and Margaret Michalska ⁴, ¹Arthritis Northwest; Discus Analytics, Spokane, WA, ²Discus Analytics, Spokane, WA, ³Axio Research, Seattle, WA, ⁴Genentech, Inc., South San Francisco, CA
Background/Purpose: For patients with giant cell arteritis (GCA) and/or polymyalgia rheumatica (PMR), glucocorticoids are the mainstay of treatment. However, due to the chronic nature of…
Abstract Number: 2260 • 2019 ACR/ARP Annual Meeting
Patients’ Journeys Through Giant Cell Arteritis: A Qualitative Study
Jennie Best¹, Ivan Nunez ², Kristina Woodburn ², Abby Breyer ², Mike Conway ² and Margaret Michalska ¹, ¹Genentech, Inc., South San Francisco, CA, ²Azul Seven, Minneapolis, MN
Background/Purpose: Diagnosis of giant cell arteritis (GCA) is difficult due to multiple presenting symptoms, and access to care may be delayed because often multiple providers…
Abstract Number: 2670 • 2019 ACR/ARP Annual Meeting
Giant Cell Arteritis with Intracranial Vasculitis: A Case Series
Catalina Sanchez-Alvarez¹, Alexander Hawkins ¹, Matthew Koster ², Vance T. Lehman ³, Cynthia Crowson ¹ and Kenneth Warrington ², ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic Rochester, Rochester, MN, ³Mayo Clinic, Rochester
Background/Purpose: Giant cell arteritis (GCA) is a large vessel vasculitis that primarily affects the aorta and its branches. Extracranial branches of the carotid artery are…
Abstract Number: 2692 • 2019 ACR/ARP Annual Meeting
Coronary Artery Disease in a Population-Based Cohort of Biopsy-Proven Giant Cell Arteritis in Southern Sweden
Pavlos Stamatis¹, Moman Mohammad ¹, Peter Merkel ², Martin Englund ³, Carl Turesson ⁴, David Erlinge ¹ and Aladdin Mohammad ¹, ¹Lund University, Lund, Skane Lan, Sweden, ²University of Pennsylvania, Philadelphia, PA, ³Lund University, Lund, Sweden, ⁴Lund University, Malmö, Sweden
Background/Purpose: The aim of this study was to estimate the incidence rate and prevalence of coronary artery diseases (CAD) in patients with temporal artery positive…
Abstract Number: 2197 • 2018 ACR/ARHP Annual Meeting
Steroid Bolus Leads to a Negative 18f-FDG PET/CT Scan in Large Vessel Vasculitis. Data from a Multicenter Giant Cell Arteritis Cohort Database
Paula Estrada¹, Patricia Moya², Hector Corominas³, Delia Reina⁴, Dacia Cerdà⁴, Daniel Roig Vilaseca⁴, Vanessa Navarro⁴, Sergi Heredia⁴ and Francisco Javier Narváez⁵, ¹Rheumatology, Hospital Moisès Broggi-Hospital General de L´Hospitalet. Consorci Sanitari Integral, Barcelona, Spain, ²Rheumatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ³Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain, ⁴Rheumatology, Hospital Moisès Broggi-Hospital General de L´Hospitalet. Consorci Sanitari Integral,, barcelona, Spain, ⁵Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain
Background/Purpose: Giant cell arteritis (GCA) and polymialgia rheumatica (PMR) are overlapping inflammatory diseases. Large Vessel Vasculitis (LVV) is frequently present in any of the two…
Abstract Number: 2777 • 2018 ACR/ARHP Annual Meeting
Dynamics in Peripheral Blood Cell Counts in Giant Cell Arteritis before Treatment, during Treatment and in Treatment-Free Remission
Jacoba C. Graver¹, Yannick van Sleen², Wayel H. Abdulahad², Annemieke M.H. Boots², Maria Sandovici² and Elisabeth Brouwer³, ¹Rheumatoloy and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ²Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ³University of Groningen University Medical Center, Groningen, Netherlands
Background/Purpose: Giant cell arteritis (GCA) is an inflammatory disease of large vessels requiring long-term treatment with glucocorticoids. The immunopathology is characterized by vessel infiltrating innate…
Abstract Number: 2739 • 2018 ACR/ARHP Annual Meeting
Systemic Vasculitis: Incidence of Glucocorticoid Related Adverse Events
Luciano Fernando Lo Giudice¹, Marina Scolnik², Jose Maximiliano Martinez P³, Aurelia Luissi¹, Valeria Scaglioni² and Enrique R Soriano², ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Capital Federal, Argentina, ²Rheumatology Unit, Internal Medicine Service. Hospital Italiano Buenos Aires. Argentina, Buenos Aires, Argentina, ³Rheumatology, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Background/Purpose: The glucocorticoid toxicity index (GTI) (Miloslavsky et al. Ann Rheum Dis 2017) is useful to assess impact on morbility associated with these drugs. It…
Abstract Number: 2783 • 2018 ACR/ARHP Annual Meeting
EULAR Task Force Recommendations for a Minimum Core Set of Parameters to be Collected in Giant Cell Arteritis Registries and Databases
Lisa Ehlers¹, Johan Askling², Johannes W. J. Bijlsma³, Maria C. Cid⁴, Maurizio Cutolo⁵, Bhaskar Dasgupta⁶, Christian Dejaco^7,8, William G Dixon⁹, Nils Feltelius^10,11, Axel Finckh¹², Kate Gilbert¹³, Sarah Mackie¹⁴, Alfred Mahr¹⁵, Eric L. Matteson¹⁶, Lorna Neill¹⁷, Carlo Salvarani^18,19, Wolfgang A. Schmidt²⁰, Anja Strangfeld²¹, Ronald van Vollenhoven²² and Frank Buttgereit¹, ¹Department of Rheumatology and Clinical Immunology, Charité University Hospital Berlin, Berlin, Germany, ²Unit of Clinical Epidemiology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden, ³Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁴University of Barcelona, Barcelona, Spain, ⁵Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, ⁶Southend University Hospital NHS Foundation Trust, Westcliff-on-Sea, United Kingdom, ⁷Department of Rheumatology and Immunology, Medical University Graz, Graz, Austria, Graz, Austria, ⁸Rheumatology, Hospital of Bruneck, Bruneck, Italy, ⁹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ¹⁰Medical Products Agency, Uppsala, Sweden, ¹¹Cross-Committee Task Force on Registries at the European Medicines Agency, London, United Kingdom, ¹²University Hospital of Geneva, Geneva, Switzerland, ¹³Patient Representative from PMRGCAuk, London, United Kingdom, ¹⁴NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, University of Leeds, Leeds, United Kingdom, ¹⁵Internal Medicine, Saint-Louis Hospital, Paris Diderot University, Paris, France, ¹⁶Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, ¹⁷Patient Representative from PMR-GCA Scotland, Perth, United Kingdom, ¹⁸Università di Modena e Reggio Emilia, Modena, Italy, ¹⁹Azienda USL-IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia, Reggio Emilia, Italy, ²⁰Medical Center for Rheumatology and Clinical Immunology Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Germany, ²¹Epidemiology, German Rheumatism Research Center, Berlin, Germany, ²²Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, Netherlands
Background/Purpose: Giant cell arteritis (GCA) represents the most common form of primary systemic vasculitis, and is frequently associated with comorbidities related either to the disease…
Abstract Number: 2745 • 2018 ACR/ARHP Annual Meeting
Clinical and Serological Outcomes of Patients with Giant Cell Arteritis Treated with Tocilizumab or Abatacept As Steroid-Sparing Agents
Daniela Rossi¹, Irene Cecchi², Elena Rubini³, Massimo Radin⁴, Savino Sciascia⁵ and Dario Roccatello⁶, ¹Department of Medicine and Experimental Oncology, CMID - Center of Research of Immunopathology and Rare Diseases, Turin, Italy, ²Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ³Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bosco Hospital, Turin, Italy., Turin, Italy, ⁴Department of Clinical and Biological Sciences, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, ⁵Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Torino, Italy, ⁶Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin and S. Giovanni Bo, Turin, Italy
Background/Purpose: At least 2 biological therapies [tocilizumab (TCZ) and abatacept (ABA)] have been proven to be effective in the management of Giant cell arteritis (GCA)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].